Company news
Ehave Inc. news in 2021
Ehave Inc.'s news releases, calls and decks from 2021, newest first.
Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures
December 8, 2021
Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB
March 3, 2021
Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021
February 26, 2021
Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Te
February 17, 2021
Mycotopia Therapies (20/20 Global) to Launch PsyBioMed, a Biosynthetic Compound, a Biotech Company for the Global Production of Psychedelics
February 8, 2021
20/20 Global Announces It Has Applied for a Name and Stock Symbol Change with FINRA
February 8, 2021
Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression
February 1, 2021
Ehave Looks to Expand KetaDASH to Palliative Care
January 27, 2021
20/20 Global, Inc. PsyTech the World’s Most Recognized Psychedelic Conference to Host Live Webinar on New Approaches to Ketamine-Assisted Treatment Wednesday, January 27th 2021 at 12: 00 EST
January 26, 2021
Ehave, Inc. Utilizes Artificial Intelligence and Machine Learning for Big Data Management in Mental Healthcare
January 25, 2021
Ehave Closes Transaction to Acquire CureDash Assets, Adds KetaDASH Home Delivery Service for Ketamine Clinics
January 22, 2021
Ehave Revolutionizes Patient Medical Records for Psychedelic Mental Health
January 21, 2021
Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector
January 20, 2021